• By ICR Secretariat
  • Posted Thursday, August 4, 2022

Tallac announces first patient treated with TAC-001

https://www.pharmatimes.com/news/tallac_announces_first_patient_treated_with_tac-001_1452825

Tallac Therapeutics has announced that the first patient has been treated with TAC-001 in a phase 1/2 clinical trial for patients with advanced or metastatic solid tumours.